Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Kane Biotech Inc. V.KNE

Alternate Symbol(s):  KNBIF

Kane Biotech Inc. is a Canada-based biotechnology company. The Company is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. It has a portfolio of biotechnologies and products, which includes StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactiv+, DermaKB and DermaKB Biofilm. Its Wound Care & Surgical division is focused on the product development of DispersinB for applications in chronic wound care. Its bluestem product line includes water additives, chews, spray and dental wipes. Its other products in development stage include Coactiv+, antimicrobial wound rinse for use in acute and chronic wounds; Coactiv+, antimicrobial surgical hydrogel for use in surgical and acute wounds, and DispersinB Gel for prosthetic joint infection. It also provides Scalp Detoxifier, Shampoo and Shampoo Bars. Its primary markets for its technologies are animal health and human health.


TSXV:KNE - Post by User

Comment by MirrorWorldManon Mar 16, 2023 11:21pm
129 Views
Post# 35344184

RE:RE:RE:RE:RE:News Release: Further information…

RE:RE:RE:RE:RE:News Release: Further information…I read closely the details of 1year $5M credit facility from Pivot. The repayment terms are brutal, including an immediate repayment of $1M after an offering or equity investment, 15% interest rate, $1M Guarantor requirements and 2.5 M x .10 warrants. That is a desperate bridge financing and tremendous anticipation of revenue within one year. It is highly unlikely that Marc Edwards, averse to diluting as he is, would be able to raise $5 M + 15% interest to pay back that loan by issuing shares on the open market. Its a big gamble and the chips are down. Question is do we double down?
<< Previous
Bullboard Posts
Next >>